These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32274716)

  • 1. Heparanase: A Dynamic Promoter of Myeloma Progression.
    Purushothaman A; Sanderson RD
    Adv Exp Med Biol; 2020; 1221():331-349. PubMed ID: 32274716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.
    Bandari SK; Purushothaman A; Ramani VC; Brinkley GJ; Chandrashekar DS; Varambally S; Mobley JA; Zhang Y; Brown EE; Vlodavsky I; Sanderson RD
    Matrix Biol; 2018 Jan; 65():104-118. PubMed ID: 28888912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
    Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
    Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma.
    Ramani VC; Zhan F; He J; Barbieri P; Noseda A; Tricot G; Sanderson RD
    Oncotarget; 2016 Jan; 7(2):1598-607. PubMed ID: 26624982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.
    Purushothaman A; Chen L; Yang Y; Sanderson RD
    J Biol Chem; 2008 Nov; 283(47):32628-36. PubMed ID: 18812315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
    Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y
    Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity.
    Ramani VC; Yang Y; Ren Y; Nan L; Sanderson RD
    J Biol Chem; 2011 Feb; 286(8):6490-9. PubMed ID: 21131364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.
    Yang Y; Macleod V; Miao HQ; Theus A; Zhan F; Shaughnessy JD; Sawyer J; Li JP; Zcharia E; Vlodavsky I; Sanderson RD
    J Biol Chem; 2007 May; 282(18):13326-33. PubMed ID: 17347152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes.
    Thompson CA; Purushothaman A; Ramani VC; Vlodavsky I; Sanderson RD
    J Biol Chem; 2013 Apr; 288(14):10093-10099. PubMed ID: 23430739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparanase promotes myeloma stemness and in vivo tumorigenesis.
    Tripathi K; Ramani VC; Bandari SK; Amin R; Brown EE; Ritchie JP; Stewart MD; Sanderson RD
    Matrix Biol; 2020 Jun; 88():53-68. PubMed ID: 31812535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.
    Yang Y; Ren Y; Ramani VC; Nan L; Suva LJ; Sanderson RD
    Cancer Res; 2010 Nov; 70(21):8329-38. PubMed ID: 20978204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
    Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
    Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparanase promotes the spontaneous metastasis of myeloma cells to bone.
    Yang Y; Macleod V; Bendre M; Huang Y; Theus AM; Miao HQ; Kussie P; Yaccoby S; Epstein J; Suva LJ; Kelly T; Sanderson RD
    Blood; 2005 Feb; 105(3):1303-9. PubMed ID: 15471949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.
    Purushothaman A; Uyama T; Kobayashi F; Yamada S; Sugahara K; Rapraeger AC; Sanderson RD
    Blood; 2010 Mar; 115(12):2449-57. PubMed ID: 20097882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear Heparanase Regulates Chromatin Remodeling, Gene Expression and PTEN Tumor Suppressor Function.
    Amin R; Tripathi K; Sanderson RD
    Cells; 2020 Sep; 9(9):. PubMed ID: 32899927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells.
    Li J; Pan Q; Rowan PD; Trotter TN; Peker D; Regal KM; Javed A; Suva LJ; Yang Y
    Oncotarget; 2016 Mar; 7(10):11299-309. PubMed ID: 26849235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of heparanase in tumor progression: Molecular aspects and therapeutic options.
    Masola V; Zaza G; Gambaro G; Franchi M; Onisto M
    Semin Cancer Biol; 2020 May; 62():86-98. PubMed ID: 31348993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.
    Sanderson RD; Elkin M; Rapraeger AC; Ilan N; Vlodavsky I
    FEBS J; 2017 Jan; 284(1):42-55. PubMed ID: 27758044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
    Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
    Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparanase enhances myeloma progression via CXCL10 downregulation.
    Barash U; Zohar Y; Wildbaum G; Beider K; Nagler A; Karin N; Ilan N; Vlodavsky I
    Leukemia; 2014 Nov; 28(11):2178-87. PubMed ID: 24699306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.